Nafamostat is expected to prevent the transmission of new coronavirus infection (COVID-19)

(The Institute of Medical Science, The University of Tokyo) Nafamostat mesylate (brand name: Fusan), which is the drug used to treat acute pancreatitis, may effectively block the requisite viral entry process the new coronavirus (SARS-CoV-2) uses to spread and cause disease (COVID-19). The University of Tokyo announced these new findings on March 18, 2020.

https://www.eurekalert.org/pub_releases/2020-03/tiom-nie032420.php

Source: EurekAlert! - Biology - March 30, 2020 Category: Biology Source Type: news